Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cardiovascular Systems (CSII – Research Report) and SELLAS Life Sciences Group (SLS – Research Report).
Cardiovascular Systems (CSII)
In a report released today, Michael Matson from Needham maintained a Hold rating on Cardiovascular Systems. The company’s shares closed last Thursday at $14.20, close to its 52-week low of $12.26.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Cardiovascular Systems.
See Insiders’ Hot Stocks on TipRanks >>
SELLAS Life Sciences Group (SLS)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on SELLAS Life Sciences Group, with a price target of $12.00. The company’s shares closed last Thursday at $4.08.
According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of
SELLAS Life Sciences Group has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CSII:
- Altice Nosedives on Subscriber Loss Concerns
- Deutsche Bank Sticks to Its Hold Rating for Marriott International (MAR)
- H.C. Wainwright Sticks to Its Buy Rating for MiNK Therapeutics (INKT)
- ASM JOINS SEMICONDUCTOR CLIMATE CONSORTIUM AS FOUNDING MEMBER
- H.C. Wainwright Remains a Buy on Albireo Pharma (ALBO)